Similar articles

Abstract: Background: Statins have proven efficacy in inhibiting the onset and progress of atherosclerosis. The effectiveness of pitavastatin in reversing carotid atherosclerosis associated with hypercholesterolemia (HC) is unknown. Objectives: To explore the simultaneous effects of pitavastatin calcium on brachial arterial flow-mediated vasodilatation (FMD), carotid intima-media thickness (IMT), and arterial stiffness (β), three surrogate markers of atherosclerosis were studied in HC patients. Methods: A randomized, double-blind trial was performed with 40 HC subjects who fulfilled the inclusion/exclusion criteria. Patients were given pitavastatin calcium 1 mg/d (Group 1) or 2 mg/d (Group 2) for 8 weeks. There were 20 patients in each group, and 30 gender- and age-matched healthy subjects as controls were recruited. FMD of the brachial artery, carotid IMT, and arterial stiffness indicated by β were measured at baseline and at 8 weeks after starting pitavastatin calcium therapy using ultrasound techniques. Biochemical tests were also made on all subjects. Results: At baseline, higher total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), reduced FMD, and increased β and IMT were observed in HC patients (P<0.001 for all) compared with controls. After 8 weeks, TC was decreased by 20.59%/27.56% and LDL-C 30.92%/35.64%, respectively, in comparison to baseline groups; the HC groups had reduced β and improved endothelial function over the 8-week follow-up (P<0.05–0.001); nonetheless, no significant alterations of IMT were found (P>0.05). Significant negative interactions between TC/LDL and FMD (P<0.05–0.001), positive interactions between TC and IMT (P=0.003) and between TC/LDL and β (P<0.001–0.000) were found. Conclusions: Treatment with pitavastatin calcium exerted favorable effects on endothelial function and arterial stiffness. It also improved carotid atherosclerosis in patients with HC.

匹伐他汀钙对高胆固醇血症患者动脉粥样硬化的影响

[1]Anderson, T.J., 2006. Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk. Can. J. Cardiol., 22(Suppl. B):72B-80B.

[2]Anderson, T.J., Uehata, A., Gerhard, M.D., et al., 1995. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol., 26(5):1235-1241.

[3]Barter, P., Gotto, A.M., LaRosa, J.C., et al., 2007. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med., 357(13):1301-1310.

[4]Bonetti, P.O., Lerman, L.O., Lerman, A., 2003. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb. Vasc. Biol., 23(2):168-175.

[5]Bots, M.L., Hoes, A.W., Koudstaal, P.J., et al., 1997. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation, 96(5):1432-1437.

[6]Burke, G.L., Evans, G.W., Riley, W.A., et al., 1995. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 26(3):386-391.

[7]Chen, E.J., Adler, R.S., Carson, P.L., et al., 1995. Ultrasound tissue displacement imaging with application to breast cancer. Ultrasound Med. Biol., 21(9):1153-1162.

[8]Cho, S.H., Jeong, M.H., Park, I.H., et al., 2009. Endothelial dysfunction, increased carotid artery intima-media thickness and pulse wave velocity, and increased level of inflammatory markers are associated with variant angina. J. Cardiol., 54(2):183-191.

[9]Corretti, M.C., Anderson, T.J., Benjamin, E.J., et al., 2002. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol., 39(2):257-265.

[10]de Groot, E., Jukema, J.W., Montauban van Swijndregt, A.D., et al., 1998. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J. Am. Coll. Cardiol., 31(7):1561-1567.

[11]Dembowski, E., Davidson, M.H., 2009. A review of lipid management in primary and secondary prevention. J. Cardiopulm. Rehabil. Prev., 29(1):2-12.

[12]Diehm, C., Kareem, S., Lawall, H., 2004. Epidemiology of peripheral arterial disease. Vasa, 33(4):183-189.

[13]Galle, J., Bassenge, E., Busse, R., 1990. Oxidised low density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ. Res., 66(5):1287-1293.

[14]Hiro, T., Kimura, T., Morimoto, T., et al., 2009. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS Study). J. Am. Coll. Cardiol., 54(4):293-302.

[15]Juonala, M., Viikari, J.S., Laitinen, T., et al., 2004. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the Cardiovascular Risk in Young Finns Study. Circulation, 110(18):2918-2923.

[16]Leone, N., Ducimetière, P., Gariépy, J., et al., 2008. Distension of the carotid artery and risk of coronary events: the three-city study. Arterioscler. Thromb. Vasc. Biol., 28(7):1392-1397.

[17]Lorenz, M.W., Markus, H.S., Bots, M.L., et al., 2007. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation, 115(4):459-467.

[18]Lusis, A.J., 2000. Atherosclerosis. Nature, 407(6801):233-241.

[19]Makita, S., Ohira, A., Tachieda, R., et al., 2000. Dilation and reduced distensibility of carotid artery in patients with abdominal aortic aneurysms. Am. Heart J., 140(2):297-302.

[20]Neunteufl, T., Katzenschlager, R., Hassan, A., et al., 1997. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis, 129(1):111-118.

[21]Oliver, J.J., Webb, D.J., 2003. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler. Thromb. Vasc. Biol., 23(4):554-566.

[22]Petnehazy, T., Stokes, K.Y., Russell, J.M., et al., 2005. Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules. Hypertension, 45(2):209-215.

[23]Raitakari, O.T., Juonala, M., Kähönen, M., et al., 2003. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA, 290(17):2277-2283.

[24]Ross, R., 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362(6423):801-809.

[25]Ross, R., 1999. Atherosclerosis—an inflammatory disease. N. Engl. J. Med., 340(2):115-126.

[26]Serruys, P.W., de Feyter, P., Macaya, C., et al., 2002. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA, 287(24):3215-3222.

[27]Smilde, T.J., van Wissen, S., Wollersheim, H., et al., 2001. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet, 357(9256):577-581.

[28]Takase, B., Uehata, A., Akima, T., et al., 1998. Endothelium-dependent flow-mediated vasodilatation in coronary and brachial arteries in suspected coronary disease. Am. J. Cardiol., 82(12):1535-1539.

[29]Weidner, G., 2000. Why do men get more heart disease than women? An international perspective. J. Am. Coll. Health., 48(6):291-294.

[30]Yan, H.M., Zhao, J., Ma, D.Z., et al., 2011. The effect of pitavastatin calcium on endothelial dysfunction induced by hypercholesterolemia. Expert Opin. Pharmacother., 12(10):1463-1471.

[31]Yeboah, J., Crouse, J.R., Hsu, F.C., et al., 2007. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation, 115(18):2390-2397.

[32]Yu, X.Y., Zhao, Y., Song, X.X., et al., 2014. Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 15(10):879-887.

[33]Zanchetti, A., Bond, M.G., et al., Hennig, M., 2002. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European lacidipine study on atherosclerosis (ELISA), a randomized, double-blind, long-term trial. Circulation, 106(19):2422-2427.